Contemporary adrenal scintigraphy

  • Milton D. Gross
  • Anca Avram
  • Lorraine M. Fig
  • Domenico Rubello
Occasional survey



High-resolution computed tomography (CT) and magnetic resonance (MR) imaging have replaced scintigraphy as primary imaging modalities for the evaluation of adrenal diseases.


Thin-slice CT, CT contrast washout studies and MR pulse sequences specifically designed to identify adrenal lipid content have radically changed the approach to anatomic imaging and provide unique insight into the physical characteristics of the adrenals. With a confirmed biochemical diagnosis, further evaluation is often unnecessary, especially in diagnostic localization of diseases of the adrenal cortex. However, despite the exquisite detail afforded by anatomy-based imaging, there are not infrequently clinical situations in which the functional insight provided by scintigraphy is crucial to identify adrenal dysfunction and to assist in localization of adrenocortical and adrenomedullary disease. The introduction of hybrid PET/CT and SPECT/CT, modalities that directly integrate anatomic and functional information, redefine the radiotracer principle in the larger context of high-resolution anatomic imaging. Instead of becoming obsolete, scintigraphy is an element of a device that combines it with CT or MR to allow a direct correlation between function and anatomy, whereby the combination creates a more powerful diagnostic tool than the separate component modalities.


Scintigraphy Adrenal Adrenocortical Adrenomedullary Radiopharmaceutical 


  1. 1.
    Gross MD, Korobkin M, Hussain H, et al. Adrenal gland imaging. In: Jameson JL, DeGroot LJ, editors. Endocrinology, 5th edn. Philadelphia: Saunders; 2005; p. 2425–53.Google Scholar
  2. 2.
    Gross MD, Rubello D, Shapiro B. Is there a future for adrenal scintigraphy? Nucl Med Commun 2002;23:197–202.PubMedCrossRefGoogle Scholar
  3. 3.
    Gross MD, Shapiro B, Bui C, Shulkin B, Sisson J. Adrenal scintigraphy and metaiodobenzylguanidine therapy of neuroendocrine tumors. In: Sandler MP, Coleman RE, Patton JA, Wackers FJT, Gottschalk A, editors. Diagnostic nuclear medicine, 4th edn. Philadelphia: Lippincott Williams and Wilkins; 2003; p. 715–34.Google Scholar
  4. 4.
    Gross MD, Bui C, Shapiro B. Adrenocortical scintigraphy. In: Ell PJ, Gambhir SS, editors. Nuclear medicine in clinical diagnosis and treatment, 3rd edn. Edinburgh: Churchill and Livingstone; 2004; p. 45–52.Google Scholar
  5. 5.
    Avram A, Fig LM, Gross MD. Nuclear imaging of the adrenal gland. Semin Nucl Med 2006;36:212–27.PubMedCrossRefGoogle Scholar
  6. 6.
    Eriksson B, Bergström M, Sundin A, Juhlin C, Örlefors H, Öberg K, et al. The role of PET in the localization of neuroendocrine and adrenocortical tumors. Ann N Y Acad Sci 2002;970:159–69.PubMedGoogle Scholar
  7. 7.
    Bombardieri E, Seregni E, Villano C, Chiti A, Bajetta E. Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors. Q J Nucl Med 2004;48:150–63.Google Scholar
  8. 8.
    Kainberger F, Kurtaran A, Keinast O, Dobrozemsky G, Czerny C, Kletter K. Hybrid imaging for endocrine diseases: new perspectives. Weiner Klin Wochen 2003;115 (Suppl 2):87–90.Google Scholar
  9. 9.
    Gross MD, Valk TW, Thrall JH, Beierwaltes WH. The role of pharmacologic manipulation in adrenal cortical scintigraphy. Semin Nucl Med 1981;11:128–48.PubMedCrossRefGoogle Scholar
  10. 10.
    Gross MD, Shapiro, B. Scintigraphic studies in adrenal hypertension. Semin Nucl Med 1990;19:122–43.CrossRefGoogle Scholar
  11. 11.
    Pacak K, Eisenhofer G, Goldstein DS. Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev 2004;25:568–80.PubMedCrossRefGoogle Scholar
  12. 12.
    Minn H, Salonen A, Friberg J, Roivainen A, Viljanen T, Langsjo J, et al. Imaging of adrenal incidentalomas with PET using 11C-metomidate and 18F-FDG. J Nucl Med 2004;45:972–9.PubMedGoogle Scholar
  13. 13.
    Zettinig G, Mitterhauser M, Wadsak W, Becherer A, Pirich C, Vierhapper H, et al. Positron emission tomography imaging of adrenal masses: 18F-fluorodeoxyglucose and the 11β-hydroxylase tracer 11C-metomidate. Eur J Nucl Med Mol Imaging 2004;31:1224–30.PubMedCrossRefGoogle Scholar
  14. 14.
    Sisson JC, Frager MS, Valk TW, Gross MD, Swanson DP, Wieland DM, et al. Scintigraphic localization of pheochromocytoma. N Engl J Med 1981;305:12–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Rubello D, Bui C, Casara D, Gross MD, Fig LM, Shapiro B. Functional scintigraphy of the adrenal gland. Eur J Endocrinol 2002;147(1):13–28.PubMedCrossRefGoogle Scholar
  16. 16.
    Gross MD, Shapiro B, Shreve P. Radionuclide imaging of the adrenal cortex. Q J Nucl Med 1999;43:224–32.PubMedGoogle Scholar
  17. 17.
    Ilias I, Pacak K. Anatomical and functional imaging of metastatic pheochromocytoma. Ann N Y Acad Sci 2004;1018:495–504.PubMedCrossRefGoogle Scholar
  18. 18.
    Mamede M, Carrasquillo JA, Chen CC, Del Corral P, Whatley M, Ilias I, et al. Discordant localization of 2-[18F]-fluoro-2-deoxy-D-glucose in 6-[18F]-fluorodopamine- and [123I]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites. Nucl Med Commun 2006;27(1):31–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, et al. 123I-metaiodobenzylguanidine and 111In-octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 2001;86:685–93.PubMedCrossRefGoogle Scholar
  20. 20.
    Shapiro B, Gross MD, Shulkin B. Radioisotope diagnosis and therapy of malignant pheochromocytomas. Trends Endocrinol Metab 2001;12:469–75.PubMedCrossRefGoogle Scholar
  21. 21.
    Eriksson B, Bergström M, Sundin A, Juhlin C, Örlefors H, Öberg K, et al. The role of PET in the localization of neuroendocrine and adrenocortical tumors. Ann N Y Acad Sci 2002;970:159–69.PubMedGoogle Scholar
  22. 22.
    Yun M, Kim W, Alnafisi N, Lacorte L, Jang S, Alavi A. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med 2001;42:1795–9.PubMedGoogle Scholar
  23. 23.
    Metser U, Miller E, Lerman H, Lievshitz G, Avital S, Even-Sapir E. 18F-FDG PET/CT in the evaluation of adrenal masses. J Nucl Med 2006;47:32–7.PubMedGoogle Scholar
  24. 24.
    Sohaib SA, Hanson JA, Reznek RH, Trainer PJ, Monson JP, Grossman AB, et al. CT appearance of the adrenal glands in adrenocorticotrophic hormone-dependent Cushing syndrome. Am J Roentgenol AJR 1999;172:997–1002.Google Scholar
  25. 25.
    Schteingart DE, Seabold JE, Gross MD, Swanson D. Iodocholesterol adrenal tissue uptake and imaging in adrenal neoplasms. J Clin Endocrinol Metab 1981;52:1156–62.PubMedCrossRefGoogle Scholar
  26. 26.
    Fig LM, Ehrmann D, Gross MD, Shapiro B, Schteingart D, Glazer D. The localization of abnormal adrenal function in the ACTH-independent Cushing syndrome. Ann Intern Med 1988;109:547–53.PubMedGoogle Scholar
  27. 27.
    Khan TS, Sundin A, Juhlin C, Långström B, Bergström M, Eriksson B. 11C-metomidate imaging of adrenocortical cancer. Eur J Nucl Med Mol Imaging 2003;30:403–10.PubMedCrossRefGoogle Scholar
  28. 28.
    Hennings J, Lindhe Ö, Bergström M, Långström B, Sundin A, Hellman P. [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab 2006;91:1410–4.PubMedCrossRefGoogle Scholar
  29. 29.
    Tenenbaum F, Groussin L, Foehrenbach H, Tissier F, Gouya H, Berherat J, et al. 18F-fluorodeoxyglucose positron emission tomography as a diagnostic tool for malignancy of adrenocortical tumors? Preliminary results in 13 consecutive patients. Eur J Endocrinol 2004;150:789–92.PubMedCrossRefGoogle Scholar
  30. 30.
    Fassnacht M, Kenn W, Allolio B. Adrenal tumors: how to establish malignancy? J Endocrinol Invest 2004;27:387–99.PubMedGoogle Scholar
  31. 31.
    Rao SK, Caride VJ, Ponn R, Giakovis E, Lee SH. F-18 fluorodeoxyglucose positron emission tomography-positive benign adrenal cortical adenoma: imaging features and pathologic correlation. Clin Nucl Med 2004;29(5):300–2.PubMedCrossRefGoogle Scholar
  32. 32.
    Shimizu A, Oriuchi N, Tsushima Y. High [18F] 2-fluoro-2-deoxy-D-glucose (FDG) uptake of adrenocortical adenoma showing subclinical Cushing’s syndrome. Ann Nucl Med 2003;17(5):403–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Frilling A, Tecklenborg K, Weber F, Kühl H, Müller S, Stamatis G, et al. Importance of adrenal incidentaloma in patients with a history of malignancy. Surgery 2004;136:1289–96.PubMedCrossRefGoogle Scholar
  34. 34.
    Kloos RT, Gross MD, Francis IR. Incidentally discovered adrenal masses. Endocr Rev 1995;16:460–84.PubMedCrossRefGoogle Scholar
  35. 35.
    Boland GW, Lee MJ, Gazelle GS, Halpern EF, McNicholas MM, Mueller PR. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. Am J Roentgenol AJR 1998;171:201–4.Google Scholar
  36. 36.
    Szolar DH, Korobkin M, Reittner P, Berghold A, Bauernhofer T, Trummer H, et al. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology 2005;234:479–85.PubMedGoogle Scholar
  37. 37.
    Al-Hawary MM, Francis IR, Korobkin M. Non-invasive evaluation of the incidentally detected indeterminate adrenal mass. Best Pract Res Clin Endocrinol Metab 2005;19:277–92.PubMedCrossRefGoogle Scholar
  38. 38.
    Sahdev A, Reznek RH. Imaging evaluation of the non-functioning indeterminate adrenal mass. Trends Endocrinol Metab 2004;15:272–6.Google Scholar
  39. 39.
    Korobkin M, Brodeur FJ, Francis IR, Quint LE, Dunnick NR, Londy F. CT time-attenuation washout curves of adrenal adenomas and nonadenomas. Am J Roentgenol AJR 1998;170:747–52.Google Scholar
  40. 40.
    Outwater EK, Siegelman ES, Radecki PD, Piccoli CW, Mitchell DG. Distinction between benign and malignant adrenal masses: value of T1-weighted chemical-shift MR imaging. A J Roentgenol AJR 1995;165:579–83.Google Scholar
  41. 41.
    Maurea S, Klain M, Mainolfi C, Ziviello M, Salvatore M. The diagnostic role of radionuclide imaging in evaluation of patients with nonhypersecreting adrenal masses. J Nucl Med 2004;42:884–92.Google Scholar
  42. 42.
    Maurea S, Caraco C, Klain M, Mainolfi M, Salvatore M. Imaging characterization of non-hypersecreting adrenal masses. Comparison between MR and radionuclide techniques. Q J Nucl Med Mol Imaging 2004;48:188–97.PubMedGoogle Scholar
  43. 43.
    Francis IR, Korobkin M. Pheochromocytoma. Radiol Clin North Am 1996;34:1101–12.PubMedGoogle Scholar
  44. 44.
    Ilias I, Pacak K. Diagnosis and management of tumors of the adrenal medulla. Horm Metab Res 2005;37:717–21.PubMedCrossRefGoogle Scholar
  45. 45.
    Shapiro B, Sisson J, Kalff V, Glowniak J, Satterlee W, Glazer G, et al. The location of middle mediastinal pheochromocytomas. J Thorac Cardiovasc Surg 1984;87:814–20.PubMedGoogle Scholar
  46. 46.
    Hay RV, Gross MD. Scintigraphic imaging of the adrenals and neuroectodermal tumors. In: Henkin RE, Bova D, Karesh SM, Dillehey GL, Wagner RH, Halama JR, Zimmer AM, editors. Nuclear medicine, 2nd edn. Philadelphia: Mosby; 2006; p. 820–44.Google Scholar
  47. 47.
    Ilias I, Shulkin B, Pacak K. New functional imaging modalities for chromaffin tumors, neuroblastoma and ganglioneuromas. Trends Endocrinol Metab 2005;16:66–72.PubMedCrossRefGoogle Scholar
  48. 48.
    Trampal C, Engler H, Juhlin C, Bergström M, Långström B. Pheochromocytomas: detection with 11C hydroxyephedrine PET. Radiology 2004;230:423–8.PubMedGoogle Scholar
  49. 49.
    Ilias I, Jorge JY, Carrasquillo JA, Chen CC, Eisenhofer G, Whatley M, et al. Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab 2003;88:4083–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Milton D. Gross
    • 1
    • 2
  • Anca Avram
    • 1
  • Lorraine M. Fig
    • 1
    • 2
  • Domenico Rubello
    • 3
  1. 1.Department of Radiology, Division of Nuclear MedicineUniversity of MichiganAnn ArborUSA
  2. 2.Nuclear Medicine Service (115)Department of Veterans Affairs Health SystemAnn ArborUSA
  3. 3.Nuclear Medicine Service-PET Unit, S. Maria della Misericordia Rovigo HospitalIstituto Oncologico Veneto (IOV)RovigoItaly

Personalised recommendations